Fundraising FoxCNS Pharmaceuticals
NASDAQ: CNSPHouston, US · Nevada corporation
Find your way into CNS Pharmaceuticals
Sign up to see every warm intro you have to CNS Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CNS Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CNS Pharmaceuticals is a biotechnology company developing therapies for neurological and oncological diseases with significant unmet medical needs. The company focuses on identifying and advancing differentiated therapeutic candidates to improve patient outcomes.
Founders & leadership
RL
Rami LevinPresident & Chief Executive OfficerHe has over 30 years of experience in life sciences leadership across early-stage companies and public firms, with background in drug development, commercialization of oncology and specialty therapies, M&A, and capital formation, including prior CEO roles at Saniona and ImStem Biotechnology and leadership positions at Sobi North America and Merck KGaA/Serono.
LK
Lynne KelleyChief Medical Officer
EF
Eric FaulknerChief Technology Officer
DW
Dylan WenkeChief Business Officer
Board
AM
Amy MaheryBoard director
JK
Jeffry KeyesBoard director
FC
Faith CharlesBoard director
MF
Michal FisherBoard director
BC
Bettina CockroftBoard director
Reported raises · per SEC filings
Form D private placements$22.5M disclosed across 1 round · 2026
▶$22.5MraisedMay 2026 · 13 investors · PharmaceuticalsRule 506(b)
▶$22.5MraisedMay 2026 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rami LevinExecutive Officer, Director
- Amy MaheryDirector
- Jeffry KeyesDirector
- Steve O'LoughlinExecutive Officer
- Faith CharlesDirector
- Michal FisherDirector
- Bettina CockroftDirector
- Offering amount
- $22.5M
- Amount sold
- $22.5M
- Sales commissions
- $1.6M
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- May 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
CenexelCenExel operates a network of clinical research centers that conduct trials and studies to advance new medical treatments. The company serves pharmaceutical sponsors, biotech firms, and patients by providing clinical research infrastructure and expertise across 18 sites in the United States.
Companies working in the same space as CNS Pharmaceuticals.
In the news
Frequently asked questions
- What does CNS Pharmaceuticals do?
- CNS Pharmaceuticals is a biotechnology company developing therapies for neurological and oncological diseases with significant unmet medical needs. The company focuses on identifying and advancing differentiated therapeutic candidates to improve patient outcomes.
- How much funding has CNS Pharmaceuticals raised?
- CNS Pharmaceuticals has disclosed $22.5M raised across 1 round.
- Where is CNS Pharmaceuticals headquartered?
- CNS Pharmaceuticals is headquartered in Houston, US.